For the year ending 2025-12-31, DNA had -$393,372K decrease in cash & cash equivalents over the period. -$178,724K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -312,763 |
| Depreciation and amortization | 58,990 |
| Stock-based compensation | 81,546 |
| Goodwill impairment | 0 |
| Restructuring related impairment charges | 0 |
| Non-cash customer consideration | 0 |
| Loss on equity method investments | 0 |
| Loss on investments | -16,411 |
| Change in fair value of notes receivable | 5,685 |
| Change in fair value of warrant liabilities | 0 |
| Change in fair value of contingent consideration liability | 4,232 |
| Loss on deconsolidation of subsidiaries | 0 |
| Impairment of long-lived assets | 0 |
| Deferred income tax benefit | -1,364 |
| Loss on disposal of equipment | 0 |
| Non-cash lease expense | 30,082 |
| Non-cash in-process research and development | 0 |
| Accretion of discount on marketable securities | 3,390 |
| Other non-cash activity | -2,064 |
| Accounts receivable (357, 156 and 816 from related parties) | 1,473 |
| Prepaid expenses and other current assets | 5,247 |
| Operating lease right-of-use assets | -3,814 |
| Other non-current assets | -296 |
| Accounts payable | -2,992 |
| Accrued expenses and other current liabilities | 10,376 |
| Deferred revenue, current and non-current ((8,147), (51,422) and (17,018) from related parties) | -32,393 |
| Operating lease liabilities, current and non-current | -27,932 |
| Other non-current liabilities | 11,463 |
| Net cash used in operating activities | -171,059 |
| Purchases of marketable debt securities | 418,630 |
| Maturities of marketable debt securities | 159,483 |
| Proceeds from sale of marketable debt securities | 25,899 |
| Purchases of property and equipment | 7,665 |
| Deconsolidation of subsidiaries - cash | 0 |
| Business acquisitions, net of cash acquired | 0 |
| Purchases of notes receivable | 0 |
| Proceeds from sales of marketable equity securities | 0 |
| Proceeds from sale of equipment | 574 |
| Other | -50 |
| Net cash used in investing activities | -240,289 |
| Proceeds from atm offering | 19,469 |
| Payment of issuance costs related to atm offering | 1,340 |
| Proceeds from exercise of stock options | 0 |
| Taxes paid related to net share settlement of equity awards | 0 |
| Principal payments on finance leases | 354 |
| Contingent consideration payment | 0 |
| Payment of equity issuance costs and other | 0 |
| Net cash provided by (used in) financing activities | 17,775 |
| Effect of foreign exchange rates on cash and cash equivalents | 201 |
| Net decrease in cash, cash equivalents and restricted cash | -393,372 |
Ginkgo Bioworks Holdings, Inc. (DNA)
Ginkgo Bioworks Holdings, Inc. (DNA)